Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
118
Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer
  • Industry veteran, Dr. Hutchins, to advance Heat’s platform technologies and pursue immunotherapy combinations
  • Former CSO Taylor Schreiber, M.D., Ph.D., to chair Heat’s Scientific Advisory Board and advance Shattuck Labs, Inc., a new biotechnology company focused on developing technology exclusively licensed from Heat

DURHAM, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX ), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced the appointment of Jeff Hutchins, Ph.D., as Chief Scientific Officer and Senior Vice President of Preclinical Development. Dr. Hutchins will be overseeing Heat’s research efforts, bringing over 24 years of research and clinical development experience from both large pharmaceutical and biotechnology companies.

Most recently, Dr. Hutchins served as Vice President of Preclinical Research for Peregrine Pharmaceuticals, Inc., a biopharmaceutical company developing therapeutics to fight cancer and infectious diseases.   Dr. Hutchins was responsible for building out the research program for Peregrine’s lead product candidate, bavituximab, a chimeric monoclonal antibody designed to target phosphatidylserine.  Currently in clinical development, bavituximab is being evaluated in combination through Peregrine-funded trials and strategic collaborations, including AstraZeneca and the National Comprehensive Cancer Network (NCCN). 

“I would like to welcome Dr. Hutchins to the Heat team,” commented Jeff Wolf, Heat’s Chief Executive Officer.  “He brings a tremendous amount of industry experience, including preclinical research, clinical development and manufacturing.  His expertise aligns with Heat’s current pipeline and priorities, and positions us strongly as we move into 2017.” 

“This is a bittersweet announcement for Heat, as Dr. Schreiber has been with Heat since inception and has played an instrumental role in advancing our ImPACT and ComPACT platform technologies,” added Mr. Wolf.  “Taylor will be joining Shattuck Labs, a biotechnology company focused on agonist redirected checkpoint therapeutics for cancer immunotherapy, as their CSO.  Shattuck Labs is independently funded by outside investors and Heat has the potential to benefit from the success of Shattuck through milestone and royalty payments as they advance their product candidates.  We look forward to continuing to work with Taylor in his newly appointed role as Chairman of our Scientific Advisory Board.”

“I am excited to be joining Jeff and his team at Heat, and to be continuing my pursuit in immuno-oncology and infectious diseases,” stated Dr. Hutchins.  “I understand both the challenges and rewards of working within a start-up biotechnology environment, and am looking forward to offering my expertise in continuing to advance product candidates into the clinic and hopefully into the marketplace.”  

Prior to joining Peregrine in 2012, Dr. Hutchins served as Vice President, Preclinical Development at Inhibitex Inc, which was acquired by Bristol-Myers Squibb.  From 1991 to 2000, Dr. Hutchins held several senior scientist positions in Discovery Research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College.  Dr. Hutchins earned a B.S. in Biology from Oral Roberts University, a Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at the M.D. Anderson Cancer Center and conducted postdoctoral training in the University of Southern California’s Department of Microbiology at the Norris Cancer Center. Dr. Hutchins’ publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology.

About Heat Biologics, Inc. Heat Biologics, Inc. (Nasdaq: HTBX ) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT , form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response.  Currently, Heat is conducting a Phase 1b trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).

Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami. The Zolovax patent portfolio also includes gp96 vaccines targeting West Nile virus, Dengue and yellow fever among others.

For more information, please visit www.heatbio.com .

Forward Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events.  In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions.  These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential to benefit to be received by Heat from the license with Shattuck Labs, Dr. Schreiber continuing to play a role with Heat, the belief that Heat has a strong position moving forward, Heat continuing to advance product candidates into the clinic and hopefully into the marketplace, the contributions to be made by Dr. Hutchins and the potential of Heat’s ImPACT and ComPACT therapies.  These statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements, including the ability of Heat to successfully integrate Dr. Hutchins into its management team, the ability of Shattuck to successfully develop its product candidates and for Heat to receive royalty or milestone payments from Shattuck, the ability of Heat's ImPACT and ComPACT therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, the company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the company’s  ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, the company’s ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its  ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and its ability to retain its key scientists or management personnel and the other factors described in the company’s annual report on Form 10-K for the year ended December 31, 2015 and other filings with the SEC.  The information in this release is provided only as of the date of this release and the company undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Contact: Jennifer Almond Investor and Media Relations 919-240-7133 Investorrelations@heatbio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 406

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 7

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 70

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 50

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 97

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 63

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 5

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 67

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding DraftKings Options Activity and Market Trends

Updated Category News Views 194

DraftKings: Analyzing Recent Options Activity In the world of financial trading, few stories capture attention quite like a company's options activity, especially when it comes to a prominent name such as DraftKings (NASDAQ: DKNG). Recently, significant bullish moves by major investors have been noted, illustrating a dynamic shift within the trading environment. Insights...

Continue Reading
Integrating Bitcoin into Modern Investment Strategies

Updated Category News Views 259

Why Bitcoin Is Essential in Today's Investment Landscape For many investors, Bitcoin remains a puzzling investment vehicle. A recent survey revealed that a significant portion of the population lacks confidence in the safety and reliability of cryptocurrencies. However, when industry leaders like BlackRock make statements regarding Bitcoin, it’s wise to take heed....

Continue Reading
Strengthening Global Ties: ICAC's Role in Combating Corruption

Updated Category News Views 240

Strengthening Global Ties: ICAC's Role in Combating Corruption In a significant development, the ICAC Commissioner Mr. Woo Ying-ming represented the International Association of Anti-Corruption Authorities (IAACA) at the G20 Anti-Corruption Working Group meeting, marking the first occasion for the ICAC to participate in such a global dialogue. The meeting brought together...

Continue Reading
FlexTV's New Release: A Drama of Love and Intrigue

Updated Category News Views 447

FlexTV Unveils English Adaptation of a Short Drama Mega Matrix Inc. (NYSE American: MPU) is thrilled to announce the premiere of its much-anticipated short drama Drink Me, Keep Me, Cut Me, now available in English on their streaming platform, FlexTV. This series offers viewers a tantalizing glimpse into the intricate relationship dynamics intertwined with love and...

Continue Reading
Canada Eases Mortgage Switch Process for Borrowers

Updated Category News Views 87

Canada's Mortgage Game-Changer: Easing Lender Switching In a bold move that could shake up the housing market, Canada’s banking regulator has rolled out a directive set to streamline how homeowners switch lenders during mortgage renewals. Finally! This change aims to chop through the red tape that often kept borrowers shackled to less favorable terms. The Short-Term...

Continue Reading